The International Organization for Migration coordinates US travel for refugees and manages many predeparture health assessments. To describe COVID-19 predeparture test results, we analyzed International Organization for Migration testing data for all refugees who entered the United States during November 24, 2020–June 11, 2022 (the last day for which predeparture testing was required for US-bound flights). To determine COVID-19 vaccination coverage, we queried the CDC Electronic Disease Notification system (5) for adult refugees (>18 years of age) who entered the United States during November 24, 2020–December 31, 2022. During that period, most COVID-19 vaccinations were administered through national programs; analyses were limited to adults because most countries had not yet extended vaccination programs to minors. Testing and vaccination data were not linked.

We recorded test type as reverse transcription PCR, rapid antigen test, or other. Refugees could receive >1 test. Persons were considered to have tested positive if >1 test was positive, negative when >1 test was negative and no tests were positive, and unknown when all tests were indeterminate or missing. We calculated the percentage of persons who tested positive by dividing the number of persons with >1 positive result by the number of persons with known results. For the percentage positive over time, we only included persons in calculations for the first period in which they tested positive. We defined completion of a primary vaccine series as receipt of 1 dose of a single-dose vaccine or 2 doses (regardless of time interval) of a 2-dose series authorized in the United States or listed for emergency use by the World Health Organization (WHO).

Among 24,361 refugees who arrived in the United States during November 2020–June 2022, a total of 29,025 predeparture COVID-19 tests were documented. We excluded 560 missing or indeterminate test results (including results from 389 persons for whom all tests were indeterminate or missing), leaving 23,972 persons receiving 28,465 tests (Appendix). Most (85.0%) persons had 1 test, 12.0% had 2 tests, 2.2% had 3 tests, 0.6% had 4 tests, and 0.2% had 5–10 tests. Among all tests, 2.6% were positive for COVID-19. By type, positivity was 2.7% among 24,853 reverse transcription PCR tests, 2.0% among 3,590 rapid antigen tests, and 9.0% among 22 unspecified tests. Among 23,972 persons, 2.6% had >1 positive test.

Figure 1

Figure 1. Predeparture COVID-19 test positivity among refugees by week of arrival in the United States (November 24, 2020–June 11, 2022) in study of test results and vaccination coverage among US-bound refugees,...

The percentage positive was highest in Asia (4.1%), followed by Sub-Saharan Africa (2.9%) and the Americas (2.9%), and lowest in the Middle East/North Africa (1.9%) and Europe (1.8%) (Table 1). Within each region, percentage positive varied by country (Table 1). Over time, the percentage positive ranged from 0% in April 2021 to 21.7% in October 2021 (Figure 1). Across age groups, results were similar, ranging from 2.3% among children <5 years of age to 2.8% among adults >55 years of age.

Figure 2

Figure 2. Predeparture completion of a primary COVID-19 vaccine series among adult refugees by month of arrival in the United States (November 24, 2020–December 31, 2022) in study of test results and...

During November 2020–December 2022, a total of 24,831 adult refugees arrived in the United States (Appendix). Of those, 2,509 (10.1%) received a single-dose COVID-19 vaccine series, 1,030 (4.1%) received only 1 dose of a 2-dose vaccine series, and 7,878 (31.7%) received 2 doses of a 2-dose vaccine series (Table 2). In total, 41.8% of refugees completed a primary series before arrival in the United States. Coverage increased over time (Figure 2); by December 2022, a total of 71.3% had completed a primary series. The Americas had the highest percentage of persons who completed a primary series (63.4%), followed by Asia (51.0%), Middle East/North Africa (49.4%), Sub-Saharan Africa (34.8%), and Europe (15.7%) (Table 2).

The COVID-19 pandemic severely disrupted refugee resettlement. Such disruptions can prolong uncertainty and vulnerability for refugees, delay family reunification, and strain resources for host countries and humanitarian agencies (6). Even short disruptions can lead to a cascading derailment of administrative processes. Strategies to minimize disruption while preventing pathogen importation were needed.

Universal testing for US-bound refugees represented one such strategy. Despite concerns of heightened infection risk among refugees, predeparture testing showed low prevalence. For 23,972 US-bound refugees, just 2.6% of tests were positive, below the WHO 5% threshold for countries to reopen (7) and the 10.1% test positivity found in the general US population during the same period (8).

COVID-19 vaccines represented an additional tool to minimize resettlement disruptions while protecting refugees from severe disease; however, vaccine rollout to refugee populations was hampered by variable global distribution of vaccines, resulting in reduced initial access in low- and middle-income countries (9). Among US-bound refugees, those who had an overseas health assessment in Middle East/North Africa, Asia, and the Americas had higher COVID-19 vaccination coverage than those assessed in Sub-Saharan Africa or Europe, suggesting greater barriers to vaccination in those regions. In Sub-Saharan Africa, barriers included insufficient vaccine supply and cold chain issues in remote areas. In Eastern Europe, some refugees received vaccines not approved for use in the United States or listed by WHO and thus were not counted in our calculations, and vaccine hesitancy was widespread (10). Other challenges included administrative difficulties, requirements for identity documents, and language barriers.

Despite challenges, COVID-19 vaccination coverage among US-bound refugees steadily increased over time, approaching coverage observed for the general US adult population. Within 1 month of US vaccination programs expanding to include adults <65 years of age on April 19, 2021, a total of 57.0% of the general US adult population had received >1 dose (11); by December 2022, that figure was 88.4% (12). For US-bound adult refugees, 54% had received 1 dose by April 2022 and 71.3% by December 2022, exceeding WHO’s strategic objective for all countries to reach 70% (13). Although no vaccinations are mandatory for US-bound refugees, refugees were successfully referred to national vaccination programs in their country of examination for voluntary vaccination.

In conclusion, positivity for COVID-19 among US-bound refugees, which was monitored in real time, remained modest throughout the study period. A predeparture testing strategy further reduced risk by identifying persons who required travel postponement while permitting safe travel for others. Vaccination coverage among US-bound refugees improved over time, drawing near to that of the general US population. Our findings highlight the importance of including refugees in public health initiatives during global health emergencies, demonstrating that such approaches can protect the safety and continuity of resettlement efforts.